InflaRx N.V.

InflaRx N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing inhibitors using C5a technology. C5a is an inflammatory mediator involved in autoimmune and inflammatory diseases. The company's lead product candidate is vilobelimab, a first-in-class monoclonal anti-human complement factor C5a antibody, currently in Phase 3 clinical trials for treating patients with early septic organ dysfunction. Vilobelimab has demonstrated unique C5a blocking ability and selectivity. InflaRx also has Izicopan, an oral, low molecular weight drug targeting C5aR with high affinity and selectivity, which has completed Phase 2a trials. Additionally, IFX002, an advancement of vilobelimab technology, is in preclinical development for chronic inflammatory indications. The company operates in Germany and the United States.

InflaRx N.V. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol IFRX. The company's stock is traded in US Dollars (USD). As a foreign private issuer based in Germany, InflaRx reports its financials in USD to align with its listing on a US exchange. Investors can trade IFRX shares during regular Nasdaq trading hours, and the stock is accessible to both US and international investors through brokerage accounts that support Nasdaq-listed securities.

InflaRx N.V. operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, InflaRx focuses on researching and developing novel therapies for inflammatory and autoimmune diseases. Its work involves advanced biological technologies, particularly targeting the complement system's C5a factor. The biotechnology industry is characterized by high research and development costs, lengthy clinical trial processes, and significant regulatory oversight. InflaRx's pipeline includes both monoclonal antibodies and small molecule drugs, reflecting the diverse approaches common in biotech. The company's clinical-stage status means it has not yet commercialized any products, which is typical for many biotech firms.

InflaRx N.V. is headquartered in Jena, Germany. The company was founded in 2007 and originally named Fireman B.V., changing its name to InflaRx N.V. in 2017. InflaRx operates primarily in Germany and the United States, conducting its research, development, and clinical trials in these two countries. The company's target markets are global, focusing on patients suffering from autoimmune and inflammatory diseases. Its lead candidate, vilobelimab, is being developed for septic organ dysfunction, a condition affecting patients worldwide. InflaRx also has collaborations with US and Chinese partners, including a co-development agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd., indicating an intention to serve markets beyond Europe and North America.

InflaRx N.V. has established several strategic partnerships and agreements to advance its drug development programs. Notably, the company has a co-development agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd., which likely supports the development and potential commercialization of its therapies in China. InflaRx also has a cell line sales agreement with Catalent Pharma Solutions LLC, a global contract development and manufacturing organization, to secure production capabilities for its biologic candidates. Additionally, the company entered into a Clinical Trial Collaboration Agreement with the U.S. Department of Health and Human Services (DHHS), specifically the Administration for Strategic Preparedness and Response (ASPR), the Biomedical Advanced Research and Development Authority (BARDA), and PPD Development, L.P. (now part of Thermo Fisher Scientific). This collaboration likely provides funding and support for clinical trials, particularly for vilobelimab in septic organ dysfunction.